Furthermore, an ERK inhibitor, SCH772984, which was used to determine whether the ERK1/2 activity significantly contributed to the pro-metastatic effects of CLU silencing in lung cancer cells, dramatically inhibited ERK1/2 phosphorylation and suppressed the migration and invasion of CLU-silenced lung cancer cells (Figure 5D–F). Here, MAPK3 is linked to lung cancer.